Genprex GNPX 深 沪
已收盘 09-26 16:00:00 美东时间
0.1788
-0.006
-3.51%
华盛通- 最 高0.1923
- 今 开0.1858
- 成交量 326.39万股
- 最 低 0.175
- 昨 收 0.1853
- 总市值 598.39万
- 52周最高 3.97
- 市盈率 静 --
- 换手率 9.75%
- 52周最低 0.14
- 委 比 -93.75%
- 总股本 3346.68万
- 历史最高 778.00
- 量 比 1.23
- 振 幅 9.34%
- 历史最低 0.14
- 每 手 1
- 风险率 3.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
Gain announced the start of the Phase 1b extension study for GT-02287, allowing participants to continue treatment for an additional nine months. The Phase 1b study enrolled 21 subjects, with the final participants completing the initial 90-day dosing in December 2025. Early results will be presented at the International Congress of Parkinson’s Disease in October. Additional 90-day data, including biomarkers and functional assessments, are expect...
09-18 11:41
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers ModivCare (NASDAQ:MODV) stock increased by 69.6% to $0.95 during Frida...
08-22 20:08
Genprex Secures Patent Allowances for Gene Therapy
Genprex ( ($GNPX) ) just unveiled an update. On August 18, 2025, Genprex announ...
08-18 21:47
Genprex Q2 EPS $(0.17) Beats $(0.42) Estimate
Genprex (NASDAQ:GNPX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.42) by 59.52 percent. This is a 94.33 percent increase over losses of $(3.00) per share from the same
08-15 05:21
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
Company Achieves Multiple Clinical Development Milestones in 2025 Patient Treatment Continues in Two Lung Cancer Clinical Trials AUSTIN, Texas, Aug. 4, 2025 /PRNewswire/ -- Genprex, Inc. ("G...
08-04 20:30
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Pluri (NASDAQ:PLUR) shares moved upwards by 24.0% to $5.99 during Tues...
07-02 05:05
Genprex Announces That Its Research Collaborators Presented Positive Preclinical Data And Research From Studies Of Gpx-002 At The 2025 American Diabetes Association 85th Scientific Session In Chicago
Novel Diabetes Gene Therapy Shows Potential for Re-Dosing Using Non-Viral Delivery SystemGenprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing
06-23 21:04
Genprex Enters $12.5M Stock Purchase Agreement
Genprex ( ($GNPX) ) has issued an update. On June 11, 2025, Genprex entered int...
06-12 05:51
Genprex to Participate at BIO 2025 International Convention
AUSTIN, Texas, June 3, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for...
06-03 19:00
